pharma

The multi-billion-dollar drug sector has endured a decade of under-performance. "Pfizer’s (PFE), Eli Lilly’s (LLY), Merck's (MRK), and Bristol Myers Squibb’s (BMY) stock is trading at half of their value 10 years ago and GlaxoSmithKline (GSK) is faring slightly better at a negative 25%," reports Steven Breazzano on Seeking Alpha. » Read more

In a rare but interesting example of pharma's willingness to look outside its own industry for innovation, GlaxoSmithKline is teaming with Formula 1's McLaren Group in effort to learn from the cutting-edge technology of motor racing. » Read more

What do you do when the profitable market for a drug is small, but the medical need is huge?

You open source it. » Read more